1.3.1.1: dihydropyrimidine dehydrogenase (NAD+)
This is an abbreviated version!
For detailed information about dihydropyrimidine dehydrogenase (NAD+), go to the full flat file.
Word Map on EC 1.3.1.1
-
1.3.1.1
-
thymidine
-
riboflavin
-
1.3.1.2
-
phosphorylase
-
thymidylate
-
5-fluorouracil
-
medicine
-
2.4.2.4
-
immunotitration
-
2.1.1.45
-
2.7.1.21
-
monofunctional
-
12-o-tetradecanoylphorbol-13-acetate
-
tpa-treated
-
e-5-2-bromovinyl-2'-deoxyuridine
-
analysis
- 1.3.1.1
- thymidine
- riboflavin
-
1.3.1.2
- phosphorylase
- thymidylate
- 5-fluorouracil
- medicine
-
2.4.2.4
-
immunotitration
-
2.1.1.45
-
2.7.1.21
-
monofunctional
- 12-o-tetradecanoylphorbol-13-acetate
-
tpa-treated
-
e-5-2-bromovinyl-2'-deoxyuridine
- analysis
Reaction
Synonyms
dehydrogenase, dihydrouracil, dihydropyrimidine dehydrogenase, dihydrothymine dehydrogenase, dihydrouracil dehydrogenase (NAD+), DPD, pyrimidine deaminase/reductase, pyrimidine reductase, RibD, thymine reductase, uracil reductase
ECTree
Advanced search results
Application
Application on EC 1.3.1.1 - dihydropyrimidine dehydrogenase (NAD+)
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
analysis
-
high performance liquid chromatography method for quantification of dihydrouracil to uracil ratio in plasma and application in screening for dihydropyrimidine dehydrogenase deficiency in patients treated with 5-fluorouracil. Plasma dihydrouracil to uracil ratio values are highly correlated with the plasma 5-fluorouracil-half-life values and are significantly associated with the toxic side effects, whereas, data set provided from genetic analysis of the coding sequences of the DPD gene are found to be insufficient to explain all the cases of the 5-fluorouracil-related toxicity pattern. Assay is suitable for routine clinical use for dihydropyrimidine dehydrogenase deficiency assessment in patients prior to 5-fluorouracil administration
medicine
-
target for inhibitor design to enhance the cytotoxical effect of 5-fluorouracil in tumor cells by inhibiting the DPD activity with 5-fluorouracil as substrate
medicine
-
dihydropyrimidine dehydrogenase deficiency is known to be a major cause of severe 5-fluorouracil-related toxicity
medicine
-
DPD is a molecular marker for identifying tumor cells sensitivity in breast cancer patients receiving 5-fluorouracil-based chemotherapy